Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 696-318-8 | CAS number: 174489-43-1
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
- Report date:
- 1999
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
Test material
- Reference substance name:
- prop-2-en-1-yl 2-(5-amino-2-chlorobenzoyloxy)-2-methylpropanoate
- EC Number:
- 696-318-8
- Cas Number:
- 174489-43-1
- Molecular formula:
- C14H16ClNO4
- IUPAC Name:
- prop-2-en-1-yl 2-(5-amino-2-chlorobenzoyloxy)-2-methylpropanoate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd. Biotechnology & Animal Breeding Division. 4414 Füllinsdorf / Switzerland
- Age at study initiation: Young adult (approximately 8 - 12 weeks)
- Weight at study initiation: 212 - 271 g
- Housing: Individual
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 50 % ± 20 %
- Air changes (per hr): 13 - 14/hour
- Photoperiod (hrs dark / hrs light): 12/12 hours
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: 6 cm x 6 cm
- % coverage: 10 %
- Type of wrap if used: Test item applied evenly to whole shaved area by means of a gauze-lined semiocclusive dressing fastened
around the trunk with an adhesive elastic bandage.
REMOVAL OF TEST SUBSTANCE
- Washing: The skin was cleaned with lukewarm water.
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount applied: 200 mg per 100 g body weight.
- Concentration: 100 % (undiluted) - Duration of exposure:
- 24 hours
- Doses:
- Single dose
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Period of observation: 14 days
- Clinical observations: Checked and recorded individually within the first two hours then daily for the duration of the
observation period.
- Local tolerance: The application site was examined daily for signs of dermal irritation. Any deviations from normal were
recorded using the Draize scale
- Mortality: Checked twice daily, morning and afternoon.
- Body weight: Measured and recorded Immediately before dose administration.
- Necropsy of survivors performed: yes
Results and discussion
Effect levelsopen allclose all
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There was no mortality in the study.
- Clinical signs:
- other: There were no remarkable clinical observations for any animal.
- Gross pathology:
- Necropsy examinations revealed no observable abnormalities.
- Other findings:
- - Local tolerance: There were no remarkable findings at the application site.
Applicant's summary and conclusion
- Interpretation of results:
- study cannot be used for classification
- Remarks:
- Migrated information
- Conclusions:
- The following acute oral LD50 values were determined for CA 2219 A Intermediate of CGA 276854):
LD50 in male rats: Greater than 2000 mg/kg body weight
LD50 in female rats: Greater than 2000 mg/kg body weight
LD50 in rats of both sexes: Greater than 2000 mg/kg body weight - Executive summary:
Groups of 5 male and 5 female rats were administered a single dose of CA 2219 A (Intermediate CGA 276854) (batch no. 249-GE001/SU) by dermal application at a dose levels of 2000 mg/kg for 24 hours under semiocclusive conditions, followed by a 14 day post-treatment observation period.
There was no mortality in the study.
There were no remarkable clinical observations nor were there any remarkable findings at the application site for any animal.
A slight loss of body weight was recorded in one female during the first week after treatment.
Body weights were not affected by the treatment.
Necropsy examinations revealed no observable abnormalities.
The following acute oral LD50 values were determined for CA 2219 A Intermediate of CGA 276854):
LD50in male rats: Greater than 2000 mg/kg body weight
LD50in female rats: Greater than 2000 mg/kg body weight
LD50in rats of both sexes: Greater than 2000 mg/kg body weight
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
